Publications

 

2023

Balakrishnan PB#, Holmberg CS#, Ledezma DK, Bosque A*, Fernandes  R*. “PolyIC-coated Prussian blue nanoparticles as a dual mode HIV latency reversing agent”. Nanomedicine. Feb 3. doi: 10.2217/nnm-2022-0311. #Co-first author *Corresponding Author

Rosenthal JA, Papa MP, Sanz M, Nicholes S, Holmberg CS, Bosque A, Keswani A, Amdur R, Lynch RM, Soriano-Sarabia N, Ein D. “Antibody and T-cell responses to COVID-19 Vaccination in Common Variable Immunodeficiency and Specific Antibody Deficiency”. Ann Allergy Asthma Immunol. Feb 1. doi: 10.1016/j.anai.2023.01.025.

Sanz M, Mann BT, Ryan PL, Bosque A, Pennington DJ, Hackstein H, Soriano-Sarabia N (2023). “Deep characterization of human γδ T cell subsets defines shared and lineage-specific traits”. Frontiers Immunol. Mar 31;14:1148988.

Copertino DC Jr, Holmberg CS, Weiler J, Ward AR, Howard JN, Levinger C, Pang AP, Corley MJ, Dündar F, Zumbo P, Betel D, Gandhi RT, McMahon DK, Bosch RJ, Linden N, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Kovacs C, Benko E, Bosque A*, Jones RB* (2023). “The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells”. JCI Insight. Aug 15;e169028. *Corresponding Author

Sanz M, Weideman AMK, Ward AR, Clohosey ML, Garcia-Recio S, Selitsky SR, Mann BT, Iannone MA, Whitworth CP, Chitrakar A, Garrido C, Kirchherr J, Coffey AR, Tsai YH, Samir S, Xu Y, Copertino D, Bosque A, Jones BR, Parker JS, Hudgens MG, Goonetilleke N, Soriano-Sarabia N (2023). “Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1”. Front Immunol. Sep 6;14: 1219250.

Cobos Jiménez V, Geretz A, Tokarev A, Ehrenberg PK, Deletsu S, Machmach K, Mudvari P, Howard JN, Zelkoski A, Paquin-Proulx D, Del Prete GQ, Subra C, Boritz EA, Bosque A, Thomas R, Bolton DL (2023). “AP-1/c-Fos supports SIV and HIV-1 latency in CD4 T cells infected in vivo”. iScience. Sep 22;26(10):108015.

2022

Resop R and Bosque A. "Pharmacological Targeting of Sphingosine Kinases Impedes HIV-1 Infection of CD4 T Cells through SAMHD1 Modulation". Journal of Virology. May 11;96(9):e0009622.                                                             

Bosque A. “The cultured TCM model of HIV Latency”. Methods Molecular Biology. 2407:45-55.   

Macedo AB, Levinger C, Nguyen B, Gupta M, Cruz CRY, Chiappinelli KB, Crandall KA, and Bosque A. “3-Hydroxy-1,2,3-benzotriazin-4(3H)-one enhances NK Cell effector and memory-like functions by increasing cytokine mediated-STAT activation”. Journal of Virology. Aug 10;96(15):e0037222 

Stevenson EM*, Terry S*, Copertino D*, Leyre L, Danesh A, Weiler J, Ward AR, Khadka P, McNeil E, Bernard K, Miller I, Ellsworth GB, Johnston CD, Finkelsztein EJ, Zumbo P, Betel D, Dündar F, Duncan MC, Lapointe HR, Speckmaier S, Moran-Garcia N,  Papa MP, Nicholes S, Stover CJ, Lynch RM, Caskey M, Gaebler C, Chun TW, Bosque A, Wilkin TJ, Lee GQ, Brumme ZL, Jones RB. “SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells”. Nature Communications. Aug 19;13(1):4888. doi: 10.1038/s41467-022-32376-z. *Co-first author

2021

Cheng J, Myers TG, Levinger C, Kumar P, Kumar J, Bosque A and Catalfamo M. “IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells”. iScience. Dec 9;25(1):103588.

Levinger C, Howard JN, Cheng J, Tang P, Joshi A, Catalfamo M and Bosque A. “An ultrasensitive planar array p24 Gag ELISA to detect HIV-1 in diverse biological matrixes”. Scientific Reports. Dec 8;11(1):23682

Innis EA, Levinger C, Szaniawski MA, Williams ESCP, Alcamí J, Bosque A, Schiffer JT, Coiras M, Spivak AM, Planelles V. “Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence”. Biochem Pharmacol. Dec;194:114816.

Ren Y, Huang SH, Macedo AB, Ward AR, Alberto WDC, Klevorn T, Leyre L,  Copertino DC, Mota TM, Chan D, Truong R, Rohwetter T, Zumbo P, Dündar F, Betel D, Kovacs C, Benko E, Bosque A, Jones RB. Selective BCL-XL Antagonists Eliminate Infected Cells from a Primary Cell Model of HIV Latency but not from Ex Vivo Reservoirs. Journal of Virology. Jul 12;95(15):e0242520

Sarabia I*, Novis CL*, Macedo AB, Tanaka H, Nell R, Kakazy JC, Furler RL, Shakya B, Schubert HL, Hill CS, De Paula-Silva, Spivak AM, Trautmann L, Planelles V, Bosque A. Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform miniMAVS. Frontiers in Immunology. June 14, 12:682182.*Co-first author

Salgado M, Bosque A, Garrido C (2021). Editorial: Immunotherapies Towards HIV Cure. Frontiers in Cellular and Infection Microbiology. May 11; doi: 10.3389/fcimb.2021.655363.

Sarabia I, Huang SH, Ward AR, Jones RB, Bosque A. The Intact Non-Inducible Latent HIV-1 Reservoir is Established In an In Vitro Primary TCM Cell Model of Latency. Journal of Virology. Jan 13; 95(7):e01297-20

Heinson AI, Woo J, Mukim A, White CH, Moesker B, Bosque A, Spina C, Woelk CH, Macarthur BD, Beliakova-Bethell N. Micro RNA targets in HIV latency - insights into novel layers of latency control. AIDS Res Hum Retroviruses. Feb;37(2):109-121.

2020

Moron-Lopez S, Telwatte S, Sarabia I, Battivelli E, Montano M, Macedo A, Aran D, Butte AJ, Jones RB, Bosque A, Verdin E, Greene WG, Wong JK, Yukl SA. Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+ T cells from ART-treated individuals. PLoS Pathogens. Nov 30;16(11):e1009060

Schynkel T, Szaniawski MA, Spivak AM, Bosque A, Planelles V, Vandekerckhove L, Trypsteen W. Interferon-Mediated Long Non-Coding RNA Response in Macrophages in the Context of HIV. International Journal of Molecular Sciences. Oct 19; 21(20):7741.

Ren Y, Huang SH, Patel S, Conce Alberto WD, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RB. BCL-2 Antagonism Sensitizes Cytotoxic T Cell-Resistant HIV Reservoirs to Elimination Ex Vivo. JCI. May 1;130(5):2542-2559.

Sweeney EE, Balakrishnan PB, Powell AB, Bowen A, Sarabia I, Burga RA, Jones RB, Bosque A, Cruz CRY, Fernandes R. PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function. Nano Research. 13: 736–744.

Sorensen ES*, Macedo AB*, Resop RS, Howard JN, Nell R, Sarabia I, Newman D, Ren Y, Jones RB, Planelles V, Spivak AM, Bosque A. Structure activity relationship analysis of benzotriazine analogues as HIV-1 Latency Reversing Agents”. Antimicrobial Agents and Chemotherapy. Jul 22;64(8):e00888-20. *Co-first author

Resop RS, Fromentin R, Newman D, Rigsby H, Dubrovsky L, Bukrinsky M, Chomont N, Bosque A. Fingolimod inhibits multiple stages of the HIV-1 life cycle. PLoS Pathogens. Aug 13; 16(8): e1008679.

2019

Sarabia I, Bosque A. HIV-1 Latency and Latency Reversal: Does subtype matter?. Viruses, Nov 28; 11(12), 1104.

Szaniawski MA, Spivak AM, Bosque A, Planelles V. Sex influences SAMHD1 activity and susceptibility to HIV-1 in primary human macrophages. Journal of Infectious Diseases. Feb 15;219(5):777-785.

Trypsteen W, White CH, Mukin A, Spina CA, De Spiegelaere W, Lefever S, Planelles V, Bosque A, Woelk CH, Vandekerckhove L, Beliakova-Bethell N. Long non-coding RNAs and latent HIV – A search for novel targets for latency reversal. PLoS One. 2019 Nov 11;14(11):e0224879.

Macedo AB, Novis CL, Bosque A. Targeting Cellular and Tissue HIV Reservoirs with Toll-Like Receptor Agonists. Frontiers in Immunology. Oct 15;10:2450.

2018

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Russel Cruz C, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB (2018).Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. JCI. Feb 1; 128(20):876-889.

Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V (2018). SAMHD1 phosphorylation coordinates the anti-HIV-1 response by diverse interferons and tyrosine kinase inhibition. mBio. May 15;9(3)

Macedo AB, Novis CL, De Asis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A. (2018). Dual TLR2 and TLR7 agonists as HIV latency reversing agents. JCI Insight. Oct 4;3(19).

Top

2017

Bosque A*, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wasgoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V.* Benzotriazoles reactivate latent HIV-1 through inactivation of STAT5 SUMOylation. Cell Reports. Jan 31; 18(5): 1324-1334. *Corresponding Author

Soto R, Petersen C, Novis CL, Kubinak JL, Bell R, Stephens WZ, Lane TE, Fujinami RS, Bosque A, O’Connell RM, Round JL (2017). Microbiota promotes systemic T-cell survival through suppression of an apoptotic factor. PNAS. May 23;114(21):5497-5502.

Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB (2017). T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathogens. Sep 20;13(9):e1006629.

Larson EC, Novis CL, Martins LJ, Macedo AB, Kimball KE, Bosque A, Planelles V, Barrows LR. (2017). Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro. PLoS One. Sep 26;12(9):e0185162.

Top

2016

Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M, Bosque A, Siliciano RF, Planelles V, Hofmann O, Ho Sui S, Li JZ. HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol, 14;90(9):4511-9

Bosque A, Dietz L, Gallego-Lleyda A, Sanclemente M, Iturralde M, Naval J, Alava MA, Martínez-Lostao L, Thierse HJ, Anel A.

Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. Oncotarget, 7(20):29287-305.

White CH, Moesker B, Beliakova-Bethell N, Martins LJ, Spina CA, Margolis DM, Richman DD, Planelles V, Bosque A*, Woelk CH.* Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model. PLoS Pathogens, Nov 29;12(11):e1006026. *Corresponding author.

Spivak AM, Larragoite E, Coletti M, Macedo A, Martins LJ, Bosque A, Planelles V. Janus Kinase Inhibition Suppresses PKC-Induced Cytokine Release Without Affecting HIV-1 Latency Reversal ex vivo. Retrovirology, Dec 20;13(1):88.

Top

2015

Ramirez PW, DePaula-Silva AB, Szaniawski M, Barker E, Bosque A, Planelles V. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins. Retrovirology, 12, 65.

DePaula-Silva AB, Cassiday PA, Chumley J, Bosque A, Monteiro-Filho CM, Mahon CS, Cone KR, Krogan N, Elde NC, Planelles V. Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr. Virology, 477, 10-7.

Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Typsteen W, Bosque A*, Vanderkerckhove L*, Planelles V.* Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

AIDS Res Hum Retroviruses, Jul 14. *Corresponding author

Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Konig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK. BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53.

Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91.

Top

2014

Duverger A, Wolschendorf F, Anderson JC, Wagner F, Bosque A, Shishido T, Jones J, Planelles V, Willey C, Cron RQ, Kutsch O. Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol, 88(1), 364-76.

Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother, 58(4), 1977-86.

Bonczkowski P, De Spiegelaere W, Bosque A, White CH, Van Nuffel A, Malatinkova E, Kiselinova M, Trypsteen W, Witkowski W, Vermeire J, Verhasselt B, Martins L, Woelk CH, Planelles V, Vandekerckhove L. Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. Retrovirology, 11, 70.

Saayman S, Ackley A, Turner AM, Famiglietti M, Bosque A, Clemson M, Planelles V, Morris KV. An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther, 22(6), 1164-75.

Ramirez PW, Famiglietti M, Sowrirajan B, DePaula-Silva AB, Rodesch C, Barker E, Bosque A, Planelles V. Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4(+) T cells. Cell Rep, 7(6), 2019-30.

Murry JP, Godoy J, Mukim A, Swann J, Bruce JW, Ahlquist P, Bosque A, Planelles V, Spina CA, Young JA. Sulfonation pathway inhibitors block reactivation of latent HIV-1. Virology, 471-473, 1-12.

Top

2012

Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O. Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-kappaB activity. J Virol, 86(8), 4548-58.

Top

2011

Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog, 7(10), e1002288.

Top

2009

Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood, 113(1), 58-65.

Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog, 5(6), e1000495.

Dietz L, Bosque A, Pankert P, Ohnesorge S, Merz P, Anel A, Schnolzer M, Thierse HJ. Quantitative DY-maleimide-based proteomic 2-DE-labeling strategies using human skin proteins. Proteomics, 9(18), 4298-308.

Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Planelles V, Barker E. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog, 5(10), e1000613.

Top

2008

Bosque A, Aguilo JI, del Rey M, Paz-Artal E, Allende LM, Naval J, Anel A. Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. J Leukoc Biol, 84(2), 488-98.

DeHart JL*, Bosque A*, Harris RS, Planelles V. Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol, 82(18), 9265-72. * Co-first author

Top

2007

Martinez-Lorenzo MJ, Anel A, Saez-Gutierrez B, Royo-Canas M, Bosque A, Alava MA, Pineiro A, Lasierra P, Asin-Ungria J, Larrad L. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol, 122(1), 28-40.

Del-Rey MJ, Manzanares J, Bosque A, Aguilo JI, Gomez-Rial J, Roldan E, Serrano A, Anel A, Paz-Artal E, Allende LM. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation. Immunobiology, 212(2), 73-83.

Bosque A, Marzo I, Naval J, Anel A. Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss. Mol Immunol, 44(6), 1446-53.

Bosque A, Aguilo JI, Alava MA, Paz-Artal E, Naval J, Allende LM, Anel A. The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. Blood, 109(4), 1627-35.

Top

2006

Del-Rey M, Ruiz-Contreras J, Bosque A, Calleja S, Gomez-Rial J, Roldan E, Morales P, Serrano A, Anel A, Paz-Artal E, Allende LM. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood, 108(4), 1306-12.

Diestre C, Martinez-Lorenzo MJ, Bosque A, Naval J, Larrad L, Anel A. Generation of rabbit antibodies against death ligands by cDNA immunization. J Immunol Methods, 317(1-2), 12-20.

Top

2005

Bosque A, Pardo J, Martinez-Lorenzo MJ, Iturralde M, Marzo I, Pineiro A, Alava MA, Naval J, Anel A. Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression. J Leukoc Biol, 77(4), 568-78.

Gomez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett, 579(27), 6217-22.

Top

2004

Pardo J, Bosque A, Brehm R, Wallich R, Naval J, Mullbacher A, Anel A, Simon MM. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol, 167(3), 457-68.

Top

2003

Iturralde M, Gamen S, Pardo J, Bosque A, Pineiro A, Alava MA, Naval J, Anel A. Saturated free fatty acid release and intracellular ceramide generation during apoptosis induction are closely related processes. Biochim Biophys Acta, 1634(1-2), 40-51.

Top